Epilogue: New Drugs for Neglected Diseases

Cambridge Quarterly of Healthcare Ethics 20 (2):329-334 (2011)
  Copy   BIBTEX

Abstract

In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real rate of 7.4% annually. According to these estimates, the innovation cost per new medicine today is about $2.1 billion or $2.65 billion

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 93,590

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Regulation of Next Generation Sequencing.Gail H. Javitt & Katherine Strong Carner - 2014 - Journal of Law, Medicine and Ethics 42 (s1):9-21.
Ethics in the Outpatient Setting: New Challenges and Opportunities.Ernlé W. D. Young - 1997 - Cambridge Quarterly of Healthcare Ethics 6 (3):293.
Environmental and social implications of waste in U.s. Agriculture and food sectors.David Pimentel - 1990 - Journal of Agricultural and Environmental Ethics 3 (1):5-20.

Analytics

Added to PP
2013-12-09

Downloads
39 (#115,291)

6 months
1 (#1,912,481)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Thomas W. Pogge
Yale University

Citations of this work

No citations found.

Add more citations